

IN THE CLAIMS:

Amend Claim 9 to read:

9. An assay for determining the concentration of soluble epidermal growth factor receptor and full-length epidermal growth factor receptor in a biological sample from a human patient, the assay comprising:

- a) obtaining a biological sample from the patient;
 - b) contacting an amount of a first purified antibody that specifically reacts with a first epitope of the extracellular ligand binding domain of sErbB1 with the patient biological sample to be tested, wherein the first purified antibody is modified with a first labeling moiety;
 - c) contacting the sample with an amount of a second purified antibody that specifically reacts with a second epitope of the extracellular ligand binding domain of sErbB1, wherein the second purified antibody is modified with a second labeling moiety, and wherein the second purified antibody does not competitively inhibit the binding of the first purified antibody; and
 - d) detecting the co-presence of the first and second labels to determine the concentration of the soluble epidermal growth factor receptor complexed with the antibodies;
- wherein one of the antibodies is chosen from the group consisting of: MAb R.1 and antibodies which competitively inhibit the binding of MAb R.1 to ErbB1; and wherein the